key: cord-0915758-auh8y3gh authors: Haji Aghajani, Mohammad; Moradi, Omid; Azhdari Tehrani, Hamed; Amini, Hossein; Pourheidar, Elham; Hatami, Firouze; Rabiei, Mohammad Mahdi; Sistanizad, Mohammad title: Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID‐19; a retrospective cohort study date: 2021-06-12 journal: Int J Clin Pract DOI: 10.1111/ijcp.14434 sha: 10ee321e833f2941b3afde6de0f9a590db630841 doc_id: 915758 cord_uid: auh8y3gh PURPOSE: Considering the anti‐inflammatory effect of atorvastatin and the role of medical comorbidities such as hypertension and coronary artery disease on the prognosis of the COVID‐19 patients, we aimed to assess the effect of atorvastatin add‐on therapy on mortality caused by COVID‐19. METHODS: We conducted a retrospective cohort study, including patients who were hospitalised with confirmed diagnosis of severe COVID‐19. Baseline characteristics and related clinical data of patients were recorded. Clinical outcomes consist of in‐hospital mortality, need for invasive mechanical ventilation and hospital length of stay. COX regression analysis models were used to assess the association of independent factors to outcomes. RESULTS: Atorvastatin was administered for 421 of 991 patients. The mean age was 61.640 ± 17.003 years. Older age, higher prevalence of hypertension and coronary artery disease reported in patients who received atorvastatin. These patients have shorter hospital length of stay (P = .001). Based on COX proportional hazard model, in‐hospital use of atorvastatin was associated with decrease in mortality (HR = 0.679, P = .005) and lower need for invasive mechanical ventilation (HR = 0.602, P = .014). CONCLUSIONS: Atorvastatin add‐on therapy in patient with severe COVID‐19 was associated with lower in‐hospital mortality and reduced the risk of need for invasive mechanical ventilation which supports to continue the prescription of the medication. In hospital mortality was defined as the primary outcome for the study. The need for invasive mechanical ventilation including ventilation via endotracheal or tracheostomy tubes and length of hospital stay are considered as the secondary outcomes. Statistical analysis was performed by STATA software version 14 (StataCorp) . All included patients stratified as they received atorvastatin or not during hospitalisation. The parametric or nonparametric distribution of the quantitative data was analysed using the Kolmogorov-Smirnov test. Data description of parametric quantitative variables was reported as means ± standard deviation and non-normally distributed data reported as median (interquartile range = IQR). Qualitative variables were reported as frequency (percentage). Continues variables were compared using independent t test or Mann-Whitney U-test for normally and non-normally distributed data in bivariate analysis respectively. Categorical variables were analysed using chi-square or Fisher's exact test (in the situation in which more than 25% of the categories had frequencies below five). A P-value of less than .05 is considered significant. The crude association between atorvastatin administration and occurrence of outcomes including the need for invasive mechanical ventilation and in-hospital mortality was performed using the univariate COX proportional hazards regression model. For the selection of the best predictors, variables with a P-value of less than .2 are were considered to be analysed in multivariable COX regression analysis using a stepwise selection approach. Confounders were selected based on the recommendation of previously published epidemiological studies that reported the probable prognostic value of underlying conditions and also medications that were being used. 17 This included age, gender, body mass index (BMI) in demographics, hypertension, diabetes mellitus, coronary artery disease, chronic respiratory conditions, malignancies, immunocompromised and chronic kidney disease in comorbidities. Also, we adjusted the model for using beta-blockers and ACEIs or ARBs. 18, 19 The model was adjusted for the medications which were used to treat COVID-19. Patients with negative time to event were removed from the analysis. A Previous studies showed that patients who used statins may have decreased rate of mortality caused by Results about the effect of statins on other outcomes including need for mechanical ventilation and hospital length of stay were inconsistent. In our large-scale retrospective cohort study, we examined the effect of atorvastatin, as a lipophilic statin, on outcomes of patients with severe-to-critical form of COVID-19. In addition to decrease in mortality, we observed lower risk of need of invasive mechanical ventilation associated with atorvastatin administration and also shorter hospital length of stay in patients who received atorvastatin. 95% confident interval of hazard ratio was reported. The proportional hazard assumption for COX analysis was tested using scaled Schoenfeld residuals and the P-value of .05 or more was considered as no serious violations of the proportional hazards assumption. Nine hundred and ninety-one patients were included in the study. Regarding demographics, patients who received atorvastatin were older (P < .001), but no significant differences were observed in gender distribution and BMI between the two groups. Considering comorbidities, except for diabetes and CKD, which were more prevalent in patients who did not receive atorvastatin (P < .001), and others including hypertension (P < .001), coronary artery disease (P < .001) and malignancy (P = .012) were significantly higher in the group of patients who received atorvastatin. From laboratory data collected at baseline, CRP was significantly higher in the group of patients who received atorvastatin (P = .040). Patients who did not receive atorvastatin had a higher baseline ESR, serum creatinine and urea levels compared with those who did not. Except for hydroxychloroquine (P = .005) and corticosteroids (P = .007), there were no significant differences between the two groups in medications used to treat COVID-19. Baseline demographics, clinical and laboratory data are presented in Table 1 . Based on the crude analysis, no significant differences were observed in mortality rate between two groups (26.84% vs 25.09%, P = .221). Patients who received atorvastatin have a significantly lower hospital length of stay (P < .001). Also, this group had a lower but non-significant need for mechanical ventilation (P = .563). Results for primary and secondary outcomes are represented in Table 2 . In unadjusted COX proportional analysis, atorvastatin was asso- Table 3 . Based on the result from our study, which is in accordance with the previously performed studies, reduced need for mechanical ventilation as two important measures for pulmonary function, we could say that atorvastatin administration strongly reduces the disease severity by inhibition of the inflammatory process during the disease course. Also, these effects alongside to reduction in mortality rate, which was statistically significant, make such as myopathy. 29, 30 By considering the result of the study, we should be aware of the limitation we are facing in this study. First, this study was performed by a retrospective method which complicates control of all confounders and makes further randomised controlled trials emerge. Second, we could not evaluate the possible adverse effects of atorvastatin and also the relation between statin dose and duration with the effect and side effects of the drug. Finally, extrapolation of the results to non-hospitalised patients with moderate disease severity may not be possible as we included data related to severe form of the disease. In conclusion, we found that atorvastatin therapy has positive effects on the course of hospitalisation in patients with severe COVID-19. Mostly, these effects were seen in important outcomes of these patients, ie mortality rate, duration of hospitalisation and needs for mechanical ventilation caused by COVID-19. Prospective randomised, controlled trials are to be recommended to confirm the effect of statins on patients with viral infections, especially severe COVID-19. The authors declare no conflict of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy restrictions. Omid Moradi https://orcid.org/0000-0001-5754-535X Mohammad Sistanizad http://orcid.org/0000-0002-7836-6411 World Health Organization. WHO coronavirus disease (COVID-19) dashboard Immunopathology of hyperinflammation in COVID-19 COVID-19 and the cardiovascular system COVID-19-associated vasculitis and vasculopathy Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia Cholesterol in relation to COVID-19: should we care about it? Statins and SARS-CoV-2 disease: current concepts and possible benefits Teaching old drugs new tricks: statins for COVID-19? Association of elevated plasma interleukin-18 level with increased mortality in a clinical trial of statin treatment for acute respiratory distress syndrome Clinical course and mortality risk of severe COVID-19 Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and metaanalysis Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 Beta-adrenergic blockers as a potential treatment for COVID-19 patients In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action Statin use is associated with lower disease severity in COVID-19 infection The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents Remdesivir for the treatment of covid-19 -final Dexamethasone in hospitalized patients with covid-19 -preliminary report Tocilizumab in patients with severe COVID-19: a retrospective cohort study Anakinra for severe forms of COVID-19: a cohort study Review of therapeutic agents for the treatment of COVID-19 Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors New perspectives on antimicrobial agents: remdesivir treatment for COVID-19